Rib-X Pharmaceuticals, Inc., a New Haven, CT-based biopharmaceutical company developing new antibiotics for the treatment of serious and life-threatening infections, has closed the first tranche of a $67.5m Series 2 financing.
The round was led by new investor Vatera Healthcare Partners with participation from existing shareholders Warburg Pincus, ABS Ventures and Vox Equity Partners.
A second tranche will be closed around the end of 2012.
The company intends to use the proceeds to initiate the Phase 3 clinical program for delafloxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Delafloxacin is being developed as a therapy for use initially in hospitals prior to the availability of a specific diagnosis.
Led by Mark Leuchtenberger, CEO, Rib-X Pharmaceuticals has develoepd a proprietary drug discovery platform that provides an atomic-level, three-dimensional understanding of interactions between drug candidates and their bacterial targets and enables design of antibiotics with enhanced characteristics. The company also has in clinical development Radezolid, a next-generation IV/oral oxazolidinone designed to be a potent antibiotic permitting long-term treatment of resistant infections.
The pipeline also includes its preclinical RX-04 program, partnered with Sanofi, S.A., and other discovery stage anti-infective programs.